![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 43, 30843-30848, October 22, 1999
,
§,
,
,
,
,
,
,
,
,
,
, and
From the
Department of Metabolic Diseases, the
Department of Cardiology, and the ¶ Department of
Pathology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo,
Bunkyo-ku, Tokyo 113-8655, Japan
| |
ABSTRACT |
|---|
|
|
|---|
Squalene synthase (SS) catalyzes the reductive
head-to-head condensation of two molecules of farnesyl diphosphate to
form squalene, the first specific intermediate in the cholesterol
biosynthetic pathway. We used gene targeting to knock out the mouse SS
gene. The mice heterozygous for the mutation (SS+/ Squalene synthase (SS)1
(farnesyl-diphosphate:farnesyl-diphosphate farnesyltransferase, EC
2.5.1.21) catalyzes the reductive head-to-head condensation of two
molecules of farnesyl diphosphate to form squalene, the first specific
intermediate in the cholesterol biosynthetic pathway (1). This enzyme
is an attractive target for cholesterol-lowering therapy, because the
inhibition of this step theoretically may not perturb the nonsterol
pathway, which is a potential problem in the use of the inhibitors of
cholesterol synthesis (2). Indeed, several potent SS inhibitors, such
as squalestatins or zaragozic acids (3), 1,1-bisphosphonates (4), and
quinuclidine derivatives (5), successfully lower plasma cholesterol
levels without adverse effects in vivo.
Accumulating evidence supports the notion that cholesterol metabolism
plays an essential role in development, particularly of a like nervous
system (see Ref. 6 for review). All of the naturally occurring inborn
errors in cholesterol metabolism, such as Smith-Lemli-Opitz (SLO)
syndrome (7, 8), desmosterolosis (9), and mevalonate kinase deficiency
(10), are associated with severe developmental abnormalities. Moreover,
mice lacking apoB (11, 12), microsomal triglyceride transfer protein
(13), and megalin/gp330 (14) had anomalies in the nervous system. Recently, the Hedgehog family of proteins, which are crucial for the
pattern formation in the vertebrate embryogenesis (see Ref. 15 for
review), was shown to undergo post-translational modification by
covalent attachment of a cholesterol molecule to the biologically active amino-terminal fragment of these peptides (16). Furthermore, Patched, a putative cognate receptor for the Hedgehog protein, shares
homology with cholesterol-binding proteins (17, 18). Together, it is
tempting to hypothesize that the derangement of cholesterol synthesis
affects the development of the nervous system through distorting
Hedgehog signaling.
To test the hypothesis that cholesterol itself is essential for normal
embryogenesis and whether the reduction of SS activities is associated
with cholesterol-lowering effects, we have generated SS knockout mice.
The SS Generation of SS Knockout Mice--
A fragment (528 base pairs)
of mouse SS cDNA was amplified by using primers that were designed
based on reported sequences of mouse SS cDNA (sense primer,
5'-GTCGCAAGGATGGAGTTCGT-3', and antisense primer,
5'-GTGGCAGTACTTGTCCCAGT-3') (19). This polymerase chain reaction
product was used as a probe to clone a genomic DNA from the 129/Sv
mouse genomic library as described previously (20). A replacement-type
targeting vector was constructed; the short arm containing a 1.2-kb
PstI/BglII fragment in intron 3 and the long arm
containing a 8.5-kb EcoRV fragment spanning exons 6-7 were
inserted into the XhoI and NotI sites,
respectively, of the vector pPolIIshort-neobpA-HSVTK as described
previously (21). Thus, exons 4-5, which contained a putative catalytic site (22), were replaced by a neomycin-resistant cassette.
After linearization by digestion with SalI, the vector was
electroporated into JH1 embryonic stem cells. Targeted clones, which
had been selected in the presence of G418 and 1-(2-deoxy, 2-fluoro- Breeding Experiments--
SS+/ Diets--
Three diets were used: (i) a normal chow (MF,
Oriental Yeast), (ii) a 1.25% cholesterol diet, which contains 1.25%
(w/w) cholesterol, 5% (w/w) cocoa butter, and 0.5% (w/w) cholic acid
(23), and (iii) a 2% squalene diet, which contains 2% (w/w) squalene
(WAKO) (24). Timed mating was performed and dietary supplementation was
initiated 2 weeks before the mating.
SS Activity Assay--
Liver and testes were homogenized in a
buffer containing 15 mM nicotinamide, 2 mM
MgCl2, and 100 mM potassium phosphate, pH 7.4, and centrifuged at 10,000 × g for 20 min at 4 °C.
The supernatants were centrifuged at 105,000 × g for
1 h at 4 °C, and the resultant pellets, a microsome fraction,
were washed, resuspended in the same buffer, and stored in aliquots at
Measurement of Hepatic Cholesterol Synthesis--
Cholesterol
synthesis in the liver was estimated by a modified method of Eisele
et al. (26). In brief, 6 SS+/+ and 6 SS+/ Northern Blot Analyses--
Poly(A+) RNA was
isolated and pooled from the livers of six animals. 1.2 µg were
subjected to 1% agarose electrophoresis in the presence of formalin.
The fractionated RNA was transferred to Hybond N (Amersham Pharmacia
Biotech). The filters were hybridized to 32P-labeled
cDNA probes: the LDL receptor, 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and cholesterol 7 Plasma Lipoprotein Analyses--
After a 12-h fast, blood was
collected in tubes containing EDTA. Plasma levels of total cholesterol
(TC) and triglycerides (TG) were determined enzymatically using kits
(Determiner TC555 and Determiner TG555, Kyowa Medex). Lipoproteins
were fractionated by high performance liquid chromatography (HPLC) as
described (23), and the cholesterol contents in each lipoprotein
fraction were determined.
Morphological Studies--
Embryonic tissues were examined by
standard histological techniques.
Statistics--
Data are represented as mean ± S.D. The
Student's t test was used to compare the mean values
between two groups.
SS Knockout Mice--
Two genomic clones were isolated from
a library with a cDNA probe. The restriction mapping revealed that
one genomic clone (Fig. 1A)
consisted of 8 exons spanning more than 26 kb. A replacement-type vector, which allowed the deletion of exon 4-5, was constructed and
used to generate heterozygous SS knockout mice (SS+/ Reduction in mRNA Levels and Activities of SS in
Heterozygotes of SS Knockout Mice--
The SS mRNA levels in the
SS+/ Cholesterol Synthesis in the Liver--
If SS is the rate-limiting
step for TC synthesis, cholesterol synthesis is expected to be reduced
in the liver. However, the amounts of [14C]acetate
incorporated into cholesterol in the liver were not different between
the wild-type and SS+/ Plasma Lipoprotein Analyses--
To determine whether the
reduction in the SS activities in the liver is associated with the
changes in plasma lipoprotein profile, we determined the plasma lipid
levels. Neither plasma TC nor TG levels were different between the
wild-type and SS+/ Attempt to Rescue the Homozygotes by Feeding with Squalene or
Cholesterol--
If the embryonic lethality of the homozygotes results
from the cholesterol deficiency, it is theoretically possible that
dietary supplementation of squalene or cholesterol would reverse the
phenotype. To test this hypothesis, we fed the pregnant
SS+/ In the present study, we demonstrate that SS is essential for the
normal development of the embryo. 50% reduction in the SS activities
in the liver did not result in alterations in the plasma lipoprotein
profiles. Moreover, the lethal phenotypes of SS During the early development of animals, particularly during fetal
stage, there is a marked demand for new sterol. Cholesterol is required
for new membrane synthesis, for maintenance of existing membranes, and
for the synthesis of hormone and bile acids. As in the adult, this
cholesterol is supplied by either de novo synthesis within
the fetal compartment or by transfer from the maternal compartment to
the fetus through uptake of cholesterol carried in lipoproteins.
Previous studies have shown that sterol synthesis is markedly increased
in the developing fetus including a preimplantation embryo (27-29). In
addition, transport of maternal LDL and HDL to the fetal yolk sac is
drastically increased (30). Evidence suggests that several lipoprotein
receptor systems mediate the transfer of maternal lipoprotein: the LDL
receptor, megalin/gp330, VLDL receptor, and low density lipoprotein
receptor-related protein for the uptake of lipoproteins containing
either apoB-100 or apoE (reviewed in Refs. 6 and 31), and scavenger
receptor B-1 for the binding of apoA-I containing lipoproteins (32).
Because mice lacking the LDL receptor (21) or VLDL receptor (33) are fertile, there may be some redundancy in the receptor function. On the
other hand, mice lacking low density lipoprotein receptor-related protein (34) or megalin/gp330 (14) are embryonic lethal, suggesting the
pivotal role of these receptor in embryogenesis.
In this concern, it is noteworthy that SS The embryonic lethality of the SS As mentioned above, neural developmental anomalies are common in
mice with the induced mutations in cholesterol transport systems
(11-14), humans with genetic defects in the enzymes of the cholesterol
biosynthetic pathway (7-9), and fetuses born to animals treated with
the inhibitors of these enzymes (36, 40). These observations lead us to
the speculation that SS Recently, a link has emerged between cellular cholesterol metabolism
and signaling molecules that are crucial for early development, the
Hedgehog proteins (16-18). Drosophila Hedgehog and murine
sonic Hedgehog proteins undergo post-translational modification in
which a cholesterol moiety is attached to its amino terminus (16). Patched, the putative receptor for Hedgehog protein (17), shares homology with the Nieman-Pick C1 protein (18), HMG-CoA reductase (45),
and sterol regulatory element-binding protein cleavage-activating protein (46). This shared domain may function as a cholesterol-binding domain that is crucial for their functions. A certain part of the
developmental anomalies of SLO syndrome may be ascribed to the
defective function of the sonic Hedgehog signaling pathway; indeed,
sonic Hedgehog knockout mice develop a holoprosencephalic phenotype
similar to that in some SLO syndrome cases and in megalin-deficient mice (47). The phenotypes of SS SS+/
) were
apparently normal. SS+/
mice showed 60% reduction in the
hepatic mRNA levels of SS compared with SS+/+ mice.
Consistently, the SS enzymatic activities were reduced by 50% in the
liver and testis. Nevertheless, the hepatic cholesterol synthesis was
not different between SS+/
and SS+/+ mice,
and plasma lipoprotein profiles were not different irrespective of the
presence of the low density lipoprotein receptor, indicating that SS is
not a rate-limiting enzyme in the cholesterol biosynthetic pathway. The
mice homozygous for the disrupted SS gene (SS
/
) were
embryonic lethal around midgestation. E9.5-10.5 SS
/
embryos exhibited severe growth retardation and defective neural tube
closure. The lethal phenotype was not rescued by supplementing the dams
either with dietary squalene or cholesterol. We speculate that
cholesterol is required for the development, particularly of the
nervous system, and that the chorioallantoic circulatory system is not
mature enough to supply the rapidly growing embryos with maternal
cholesterol at this developmental stage.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
mice were lethal between E9.5 and E12.5 and
exhibited severe retardation of development. The SS+/
mice
expressed only 50% SS activities in the liver and testes compared with
SS+/+ mice, whereas their plasma lipoprotein profiles and
responses to the dietary challenge were unaffected.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-D-arabinofuranosyl)-5-iodouracil, were
identified by polymerase chain reaction using the following primers:
primer 1, 5'-ATACAGGGGAGTGTGCCTTTCTTGTG-3' and primer 2, 5'-GATTGGGAAGACAATAGCAGGCATGC-3' (Fig. 1). Homologous recombination was
verified by Southern blot analysis after
BamHI/EcoRI double digestion using a 0.5-kilobase pair PstI/XhoI fragment as a probe (Fig. 1).
Targeted embryonic stem clones were injected into the C57BL/6
blastocysts yielding five lines of chimeric mice, which transmitted the
disrupted allele through the germ line. All experiments reported here
were performed with 129/Sv-C57BL6 hybrid descendants (F1 and subsequent
generations) of these animals.
mice were cross-bred
to the LDL receptor knockout mice (LDLR
/
) (21) to
produce mice that were heterozygous for the disrupted alleles of both
SS and the LDL receptor loci. An intercross of these animals was performed.
80 °C. SS activities were measured according to a modified method
of Cohen et al. (25). In brief, the microsome fractions
(~20 µg) were incubated in 50 µl of a buffer containing 20 µM [1-3H] farnesyl pyrophosphate (25 µCi/µmol), 1 mM NADPH, 5 mM
MgCl2, 6 mM glutathione, and 100 mM
potassium phosphate, pH 7.4, at 37 °C for 15 min. Reaction was
terminated by the addition of 150 µl of chloroform/methanol (1:2,
v/v) containing 0.2% unlabeled squalene. After 50 µl of chloroform
and 50 µl of 3 M NaOH were added, the reaction mixtures
were vortexed and centrifuged. The infranatant organic phase was used
for the determination of the radioactivities in the squalene produced.
mice (9-10-week-old females) were given food and
water ad libitum and injected intraperitoneally with
[2-14C]acetate (37 kBq/kg body weight). After 30 min,
animals were euthanized, and two pieces of the liver (0.3 g/each) were
removed. [1,2-3H]cholesterol (~10,000 dpm) was added as
an internal standard, and tissue samples were saponified in 2 ml of
15% KOH, 90% ethanol at 70 °C overnight. After the addition of 2 ml of water, nonsaponified lipids were extracted with
n-hexane, evaporated, and dissolved in ethanol/acetone (1:1,
v/v). Sterols were precipitated with digitonin. After washing the
precipitates with 50% acetone, the radioactivities were determined.
The results were expressed as 14C dpm/g wet weight of
liver/30 min.
-hydroxylase.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
).
SS+/
mice, which were viable and fertile, were
intercrossed to obtain homozygous SS knockout mice
(SS
/
). No viable SS
/
mice were identified
among 149 weaned offspring, although 99 were heterozygotes (Table
I). To determine the developmental stage
where the embryos were lethal, the embryos were genotyped at four
different embryonic stages: 9.5, 10.5, 12.5, and 13.5 days postcoitum
(Table I, Fig. 1B). At E9.5-10.5, SS
/
was
identified at the frequency significantly lower than the expected
mendelian frequency (
2 = 8.35, p < 0.05). All SS
/
embryos were significantly smaller than
SS+/+ embryos with comparable developmental age.
SS
/
embryos exhibit a wide variety of morphology. Among
13 SS
/
embryos, only 1 at E9.5 showed a nearly normal
shape with a small forebrain (Fig.
2C), 6 had a shape that is
similar to E8.5 embryos, early somite-stage embryos, with an open head
fold (Fig. 2D). Their microscopic examination showed
necrotic neuronal cells with condensation of nuclei,
i.e. apoptotic cells (Fig. 2, F and
G). Four were much smaller and ambiguous and did not have
somites (Fig. 2B). At E12.5-13.5, however, no
SS
/
were identified (Table I).

View larger version (44K):
[in a new window]
Fig. 1.
Targeted disruption of the SS gene.
A, a map of the SS locus, together with the sequence
replacement gene-targeting vector and the targeted SS allele. Exons
(closed boxes) and introns (thick lines) are
indicated. The gene targeting event replaced exon 4-5 coding sequences
and intron 4 with a cassette containing a neomycin resistance gene
(Neor) driven by the RNA polymerase II promoter.
Two copies of herpes simplex virus thymidine kinase (HSV-TK)
expression cassettes were used as a negative selection marker. Analysis
of gene-targeting events and mouse genotyping was performed by Southern
blot analysis of BamHI/EcoRI-digested genomic DNA
using a 0.5-kb probe (closed bar) in intron 3. P1, primer 1; P2, primer 2; TGA, stop
codon; Kbp, kilobase pairs. B, Southern blot of
BamHI/EcoRI fragment in the targeted allele is
4.0 kb versus 5.0 kb in the wild-type allele. DNA was
isolated from whole E10.5 embryos.
Genotypes of offspring from intercrosses of SS+/
mice

View larger version (156K):
[in a new window]
Fig. 2.
Phenotype of SS
/
embryos. A, an E9.5 SS+/+ embryo with normal
developmental morphology; B, an E9.5 SS
/
embryo that lacked somite structure; C, an E9.5
SS
/
embryo that was much smaller than wild-type embryos
but apparently almost normal except for an undeveloped forebrain;
D, E10.5 SS
/
embryos that had open heads
(indicated by white arrows). Bar, 1 mm.
E, a sagittal section of an E9.5 SS+/+ embryo as
a normal control; F, a sagittal section of an E10.5
SS
/
embryo that is shown in D. The unclosed
head is indicated by an arrow. G, microscopic
examination of a part of the head that is shown in F. Some
of the cells with condensed nuclei are indicated by white
arrows. Hematoxylin eosin staining was used.
mice were reduced by 60% in the liver (Fig.
3A). Consistently, their SS
activities were significantly reduced by 50% both in the liver and
testes (Fig. 3B). In the liver, the mRNA levels of the
LDL receptor appeared to be increased by 20% in the SS+/
mice (Fig. 3A). On the other hand, the mRNA of
cholesterol 7
-hydroxylase appeared to be decreased by 20%. There
was no significant change in the mRNA levels of HMG-CoA reductase
between the SS+/+ and SS+/
mice.

View larger version (28K):
[in a new window]
Fig. 3.
SS expression and SS activities in
SS+/
mice. A, Northern blot for SS,
LDL receptor, HMG-CoA reductase, cholesterol 7
-hydroxylase, and
-actin as a loading control using liver poly(A+) RNA.
W, wild-type; H, SS+/
. B, SS
activities in the liver from SS+/+ and SS+/
mice. SS activities in the microsome prepared from the liver
(n = 6) and testis (n = 3) were
measured as described under "Experimental Procedures."
mice (10,173 ± 6444 versus 13,992 ± 10,276 dpm/g liver/30 min,
p > 0.05, n = 6).
mice, which were fed a normal chow
(Table II). There was no significant difference in the amounts of VLDL, LDL, or HDL cholesterol as measured
by HPLC (Table III). To evaluate the
effects of the suppression of SS activities in the liver on the plasma
lipoprotein profile in the setting of LDL deficiency, we further
cross-bred these animals with LDL receptor knockout mice to generate
SS+/
;LDLR
/
mice. Neither plasma TC nor TG levels were
different between the SS+/+;LDLR
/
and
SS+/
;LDLR
/
mice (Table II).
Plasma lipid levels
for either plasma TC or
TG levels, irrespective of the presence of the LDLR mutation.
HPLC lipoprotein profiles
for each lipoprotein.
mice with the diets supplemented with either 2%
squalene or 1.25% cholesterol. No viable SS
/
mice were
identified among 21 offspring for squalene rescue (4 +/+
versus 17 +/
versus 0
/
,
2 = 6.9, p < 0.05,) and 40 offspring for cholesterol
rescue (10 +/+ versus 30 +/
versus 0
/
,
2 = 6.7, p < 0.05).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
embryos
were not reversed by oral administration of either cholesterol or
squalene to the dams.
/
embryos
develop to the stage around E9.5. Results indicate that cholesterol
required for growth is exclusively supplied from the dams in
SS
/
mice. Indeed, it has not been reported that
pharmacological doses of HMG-CoA reductase inhibitors or SS inhibitors
cause preimplantation lethality (35). It is known that nonpolar
squalene, an immediate product of squalene synthase, is transported in
association with VLDL in the plasma (36) and subsequently by a squalene
and sterol carrier protein (37). Therefore, embryos may utilize
squalene that is diffused from extra embryonic tissues for cholesterol synthesis. Furthermore, in the rodents, the nutritional supply of the
embryo during the immediate postimplantation period is dependent on the
resorptive and synthetic capacity of the yolk sac (38). Presumably,
cholesterol transported across this maternal fetal barrier is utilized
for development.
/
mice may result from
either cholesterol deficiency, toxic precursor buildup, or both. The
cholesterol-supplying system in the early gestational period may no
longer be effective beyond midgestation when a functional chorioallantoic circulatory system is established (38). It is conceivable that the placental system is too immature to fully compensate for the complete deficiency of the de novo
cholesterol synthesis around this developmental stage. Belknap and
Dietschy (27) have shown that the de novo cholesterol
synthesis remains highly active during the whole midgestational
period and that the contents of newly synthesized sterols are maximal
at E17 in the rat fetus. Similar failure to catch up with the
increasing demand may underlie the lethality of mice lacking apoB (11, 12, 39) or microsomal triglyceride transfer protein (13), because both
mutants die at the same developmental stage. Alternatively, precursor
buildup may have lethal effects on the embryos as postulated for SLO
syndrome (7, 40). Inhibition of SS by compounds resulted in massive
urinary excretion of farnesol-derived dicarboxylic acids (41),
indicating the elevation of the plasma concentration of farnesol and
its metabolites. Farnesol has recently been found to be a biologically
active substance; it inhibits arterial vasoconstriction through
blocking L-type Ca2+ channels in vascular
smooth muscle cells (42, 43). Other studies have reported the existence
of a farnesol-specific, orphan nuclear receptor in vertebrate cells,
the farnesoid X-activated receptor, but its precise functions remain
unknown (44). Therefore, it is possible that farnesol or its
metabolites may have toxic effects on the embryos. This toxic precursor
buildup hypothesis may be more plausible, because supplementation of
the dams with dietary squalene failed to rescue the lethal phenotype.
/
mice develop anomalies in the
nervous system. In this regard, it is noteworthy that
SS
/
had an open neural plate (Fig. 2D). Because the general growth of SS
/
was severely impaired,
the defective neural tube closure may simply reflect general growth retardation. Interestingly, the phenotypes of SS
/
mice
are different from those of infants with SLO syndrome, despite the fact
that the responsible enzymes are involved in the proximal part of
cholesterol synthesis (8). In the SLO syndrome,
7-reductase deficiency may be partially compensated by
24-reductase, an alternative enzyme involved in the
terminal step of cholesterol biosynthesis, thereby leading to a milder
phenotype (9). The differences may also arise from either species
differences or build up of different precursors.
/
are rather similar to
Patched-deficient mice that have open and overgrown neural tubes (48).
Further studies will be needed to elucidate the similarity in the
phenotypes of these two mutants.
mice are apparently normal. Both mRNA levels and
enzymatic activities for SS were reduced by 50% in the liver, but the overall hepatic cholesterol synthesis was not reduced, confirming that
SS is not the rate-limiting enzyme in cholesterol biosynthesis (Fig.
3). The apparent changes in the LDL receptor and cholesterol 7
-hydroxylase mRNA levels may reflect hepatic cholesterol
homeostasis. In this concern, it is noteworthy that zaragozic acid, an
SS inhibitor, caused a compensatory increase in the hepatic mRNA
levels of the LDL receptor, HMG-CoA reductase, and HMG-CoA synthase as
well as SS itself along with marked suppression of cholesterol
synthesis (49). Our results, however, strongly indicate that inhibition of SS activities by 50% is not sufficient to reduce the plasma LDL
cholesterol levels with or without the functional LDL receptor at least
in mice (Table II).
| |
ACKNOWLEDGEMENTS |
|---|
We thank Mitsuyo Okazaki (Tokyo Medical Dental University) for the HPLC lipoprotein analyses; Kimiko Saito, Megumi Herai, and Mihoko Kusubae for animal maintenance; and Yoko Iizuka, Yuan Xunmei, Yoshiaki Tamura, Tetsuya Kitamine, and Hitoshi Shimano for helpful discussion.
| |
Note Added in Proof |
|---|
Bile acids have been found to be natural ligands for the FXR (50-52).
| |
FOOTNOTES |
|---|
* This work was supported by Grant-in-aid for Scientific Research 10557104 from the Ministry of Education, Science, and Culture, the Promotion of Fundamental Studies in Health Science of the Organization for Pharmaceutical Safety and Research (OPSR), and Health Sciences Research Grants (Research on Human Genome and Gene Therapy) from the Ministry of Health and Welfare.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed. Tel.: +81-3-3815-5411 (ext. 33113); Telefax: +81-3-5802-2955; E-mail: ishibash-tky@ umin.ac.jp.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: SS, squalene synthase; SLO, Smith-Lemli-Opitz; apo, apolipoprotein; kb, kilobase(s); LDL, low density lipoprotein; VLDL, very low density lipoprotein; HDL, high density lipoprotein; HMG-CoA, 3-hydroxy-3-methyglutaryl-coenzyme A; HPLC, high performance liquid chromatography; TC, total cholesterol; TG, triglycerides; LDLR, low density lipoprotein receptor; E, embryonic day.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Goldstein, J. L., and Brown, M. S. (1990) Nature 343, 425-430[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Abe, I., Tomesch, J. C., Wattanasin, S., and Prestwich, G. D. (1994) Nat. Prod. Rep. 10, 279-302 |
| 3. |
Baxter, A.,
Fitzgerald, B. J.,
Hutson, J. L.,
McCarthy, A. D.,
Motteram, J. M.,
Ross, B. C.,
Sapra, M.,
Snowden, M. A.,
Watson, N. S.,
Williams, R. J.,
and Wright, C.
(1992)
J. Biol. Chem.
267,
11705-11708 |
| 4. |
Ciosek, C. P., Jr.,
Magnin, D. R.,
Harrity, T. W.,
Logan, J. V. H.,
Dickson, J. K., Jr.,
Gordon, E. M.,
Hamilton, K. A.,
Jolibois, K. G.,
Kunselman, L. K.,
Lawrence, R. M.,
Mookhtiar, K. A.,
Rich, L. C.,
Slusarchyk, D. A.,
Sulsky, R. B.,
and Biller, S. A.
(1993)
J. Biol. Chem.
268,
24832-24837 |
| 5. |
Amin, D.,
Rutledge, R. Z.,
Needle, S. N.,
Galczenski, H. F.,
Neuenschwander, K.,
Scotese, A. C.,
Maguire, M. P.,
Bush, R. C.,
Hele, D. J.,
Bilder, G. E.,
and Perrone, M. H.
(1997)
J. Pharmacol. Exp. Ther.
281,
746-752 |
| 6. | Farese, R. V., and Herz, J. (1998) TIG (Trends Genet.) 14, 115-120 |
| 7. | Salen, G., Shefer, S., Batta, A. K., Tint, G. S., Xu, G., Honda, A., Irons, M., and Elias, E. R. (1996) J. Lipid Res. 37, 1169-1180[Abstract] |
| 8. |
Fitzky, B. U.,
Witsch-Baumgartner, M.,
Erdel, M.,
Lee, J. N.,
Paik, Y-K.,
Glossmann, H.,
Utermann, G.,
and Moebius, F. F.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8181-8186 |
| 9. | FitzPatrick, D. R., Keeling, J. W., Evans, M. J., Bell, J. E., Porteous, M. E. M., Mills, K., Winter, R. M., and Clayton, P. T. (1998) Am. J. Med. Genet. 75, 145-152[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Schafer, B. L.,
Bishop, R. W.,
Kratunis, V. J.,
Kalinowski, S. S.,
Mosley, S. T.,
Gibson, K. M.,
and Tanaka, R. D.
(1992)
J. Biol. Chem.
267,
13229-13238 |
| 11. |
Farese, R. V.,
Ruland, S. L.,
Flynn, L. M.,
Stokowski, R. P.,
and Young, S. G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
1774-1778 |
| 12. | Huang, L.-S., Voyaziakis, E., Markenson, D. F., Sokol, K. A., Hayek, T., and Breslow, J. L. (1995) J. Clin. Invest. 96, 2152-2161 |
| 13. |
Raabe, M.,
Flynn, L. M.,
Zlot, C. H.,
Wong, J. S.,
Veniant, M. M.,
Hamilton, R. L.,
and Young, S. G.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
8686-8691 |
| 14. |
Willnow, T. E.,
Hilpert, J.,
Armstrong, S. A.,
Rohlmann, A.,
Hammer, R. E.,
Burns, D. K.,
and Herz, J.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
8460-8464 |
| 15. | Tabin, C. J., and McMahon, A. P. (1997) Trends Cell Biol. 7, 442-446[Medline] [Order article via Infotrieve] |
| 16. |
Porter, J. A.,
Young, K. E.,
and Beachy, P. A.
(1996)
Science
274,
255-259 |
| 17. | Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., Jr., and Scott, M. P. (1996) Science 272, 1668-1671[Abstract] |
| 18. |
Carstea, E. D.,
Morris, J. A.,
Coleman, K. G.,
Loftus, S. K.,
Zhang, D.,
Cummings, C.,
Gu, J.,
Rosenfeld, M. A.,
Pavan, W. J.,
Krizman, D. B.,
Nagle, J.,
Polymeropoulos, M. H.,
Sturley, S. L.,
Ioannou, Y. A.,
Higgins, M. E.,
Comly, M.,
Cooney, A.,
Brown, A.,
Kaneski, C. R.,
Blanchette-Mackie, E. J.,
Dwyer, N. K.,
Neufeld, E. B.,
Cahng, T.-Y.,
Liscum, L.,
Strauss, J. F., III,
Ohno, K.,
Zeigler, M.,
Carmi, R.,
Sokol, J.,
Markie, D.,
O'Neill, R. R.,
van Diggelen, O. P.,
Elleder, M.,
Patterson, M. C.,
Brady, R. O.,
Vanier, M. T.,
Pentchev, P. G.,
and Tagle, D. A.
(1997)
Science
277,
228-231 |
| 19. | Inoue, T., Osumi, T., and Hara, S. (1995) Biochim. Biophys. Acta 1260, 49-54[Medline] [Order article via Infotrieve] |
| 20. | Osuga, J.-I., Inaba, T., Harada, K., Yagyu, H., Shimada, M., Yazaki, Y., Yamada, N., and Ishibashi, S. (1995) Biochem. Biophys. Res. Commun. 214, 653-662[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., and Herz, J. (1993) J. Clin. Invest. 92, 883-893 |
| 22. |
McKenzie, T. L.,
Jiang, G.,
Straunhaar, J. R.,
Conrad, D. G.,
and Shechter, I.
(1992)
J. Biol. Chem.
267,
21368-21374 |
| 23. |
Osuga, J.-I.,
Yonemoto, M.,
Yamada, N.,
Shimano, H.,
Yagyu, H.,
Ohashi, K.,
Harada, K.,
Kamei, T.,
Yazaki, Y.,
and Ishibashi, S.
(1998)
J. Clin. Invest.
102,
386-394 |
| 24. | Storm, H. M., Oh, S. Y., Kimler, B. F., and Norton, S. (1993) Lipids 28, 555-559[CrossRef][Medline] [Order article via Infotrieve] |
| 25. | Cohen, L. H., Griffioen, A. M., Wanders, R. J., Van Roermund, C. W. T., Huysmans, C. M. G., and Princen, H. M. G. (1986) Biochem. Biophys. Res. Commun. 138, 335-341[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Eisele, B., Budzinski, R., Muller, P., Roland, M., and Mark, M. (1997) J. Lipid. Res. 38, 564-575[Abstract] |
| 27. | Belknap, W. M., and Dietschy, J. M. (1988) J. Clin. Invest. 82, 2077-2085 |
| 28. | Jurevics, H. A., Kidwai, F. Z., and Morell, P. (1997) J. Lipid Res. 38, 723-733[Abstract] |
| 29. | Pratt, H. P. M. (1982) Dev. Biol. 89, 101-110[CrossRef][Medline] [Order article via Infotrieve] |
| 30. |
Wyne, K. L.,
and Woollett, L. A.
(1998)
J. Lipid Res.
39,
518-530 |
| 31. | Yamamoto, T., and Bujo, H. (1996) Curr. Opin. Lipidol. 7, 298-302[Medline] [Order article via Infotrieve] |
| 32. | Acton, S., Rigotti, A., Landschlz, K. T., Xu, S., Hobbs, H. H., and Krieger, M. (1996) Science 271, 518-520[Abstract] |
| 33. |
Frykman, P. K.,
Brown, M. S.,
Yamamoto, T.,
Goldstein, J. L.,
and Herz, J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8453-8457 |
| 34. | Herz, J., Clouthier, D. E., and Hammer, R. E. (1992) Cell 71, 411-421[CrossRef][Medline] [Order article via Infotrieve] |
| 35. | Liu, G. C., Ahrens, E., Jr., Schreibman, P., and Crouse, J. (1976) J. Lipid Res. 17, 38-45[Abstract] |
| 36. | Minsker, D. H., MacDonald, J. S., Robertson, R. T., and Bokelman, D. L. (1983) Teratology 28, 449-456[CrossRef][Medline] [Order article via Infotrieve] |
| 37. | Scallen, T., Srikantaiah, B., Seetharam, B., Hansbury, E., and Gavey, K. (1974) Fed. Proc. 38, 1733-1746 |
| 38. | Jollie, W. P. (1990) Teratology 41, 361-381[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Farese, R. V., Jr., Cases, S., Ruland, S. L., Kayden, H. J., Wong, J. S., Young, S. G., and Hamilton, R. L. (1996) J. Lipid Res. 37, 347-360[Abstract] |
| 40. | Repetto, M., Maziere, J. C., Citadelle, D., Dupuis, R., Meier, M., Biade, S., Quiec, D., and Roux, C. (1990) Teratology 42, 611-618[CrossRef][Medline] [Order article via Infotrieve] |
| 41. |
Bostedor, R. G.,
Karkas, J. D.,
Arison, B. H.,
Bansal, V. S.,
Vaidya, S.,
Germershausen, J. I.,
Kurtz, M. M.,
and Bergstrom, J. D.
(1997)
J. Biol. Chem.
272,
9197-9203 |
| 42. |
Roullet, J.-B.,
Xue, H.,
Chapman, J.,
McDougal, P.,
Roullet, C. M.,
and McCarron, D. A.
(1996)
J. Clin. Invest.
97,
2384-2390 |
| 43. |
Roullet, J.-B.,
Luft, U. C.,
Xue, H.,
Chapman, J.,
Bychkov, R.,
Roullet, C. M.,
Luft, F. C.,
Haller, H.,
and McCarron, D. A.
(1997)
J. Biol. Chem.
272,
32240-32246 |
| 44. | Forman, B. M., Goode, R. E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., Evans, R., and Weinberger, C. (1995) Cell 81, 687-693[CrossRef][Medline] [Order article via Infotrieve] |
| 45. | Chin, D. J., Gil, G., Russell, D. W., Liscum, L., Luskey, K. L., Basu, S. K., Okayama, H., Berg, P., Goldstein, J. L., and Brown, M. S. (1984) Nature 308, 613-617[CrossRef][Medline] [Order article via Infotrieve] |
| 46. | Hua, X., Nohturfft, A., Goldstein, J. L., and Brown, M. S. (1996) Cell 87, 415-426[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Chiang, C., Litingtung, Y., Lee, E., Young, K. E., Corden, J. L., Westphal, H., and Beachy, P. A. (1996) Nature 383, 407-413[CrossRef][Medline] [Order article via Infotrieve] |
| 48. |
Goodrich, L. V.,
Milenkovic, L.,
Higgins, K. M.,
and Scott, M. P.
(1997)
Science
277,
1109-1113 |
| 49. | Ness, G. C., Zhao, Z., and Keller, R. K. (1994) Arch. Biochem. Biophys. 311, 277-285[CrossRef][Medline] [Order article via Infotrieve] |
| 50. | Wang, H., Chen, J., Hollister, K., Sowers, L. C., and Forman, B. M. (1999) Mol. Cell. 3, 543-553[Medline] [Order article via Infotrieve] |
| 51. |
Makishima, M.,
Okamoto, A. Y.,
Repa, J. J.,
Tu, H.,
Learned, R. M.,
Luk, A.,
Hull, M. V.,
Lustig, K. D.,
Mangelsdorf, D. J.,
and Shan, B.
(1999)
Science
284,
1362-1365 |
| 52. |
Parks, D. J.,
Blanchard, S. G.,
Bledsoe, R. K.,
Chandra, G.,
Consler, T. G.,
Kliewer, S. A.,
Stimmel, J. B.,
Willson, T. M.,
Zavacki, A. M.,
Moore, D. D.,
and Lehmann, J. M.
(1999)
Science
284,
1365-1368 |
This article has been cited by other articles:
![]() |
S. Das, M. Schapira, M. Tomic-Canic, R. Goyanka, T. Cardozo, and H. H. Samuels Farnesyl Pyrophosphate Is a Novel Transcriptional Activator for a Subset of Nuclear Hormone Receptors Mol. Endocrinol., November 1, 2007; 21(11): 2672 - 2686. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Bonnans and B. D. Levy Lipid Mediators as Agonists for the Resolution of Acute Lung Inflammation and Injury Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 201 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Okazaki, F. Tazoe, S. Okazaki, N. Isoo, K. Tsukamoto, M. Sekiya, N. Yahagi, Y. Iizuka, K. Ohashi, T. Kitamine, et al. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver J. Lipid Res., September 1, 2006; 47(9): 1950 - 1958. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Levy Myocardial 15-Epi-lipoxin A4 Generation Provides a New Mechanism for the Immunomodulatory Effects of Statins and Thiazolidinediones Circulation, August 29, 2006; 114(9): 873 - 875. [Full Text] [PDF] |
||||
![]() |
G. S. Tint, H. Yu, Q. Shang, G. Xu, and S. B. Patel The use of the Dhcr7 knockout mouse to accurately determine the origin of fetal sterols J. Lipid Res., July 1, 2006; 47(7): 1535 - 1541. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A Woollett Maternal cholesterol in fetal development: transport of cholesterol from the maternal to the fetal circulation Am. J. Clinical Nutrition, December 1, 2005; 82(6): 1155 - 1161. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Lee, J.-H. Jeong, J.-W. Seo, C.-G. Shin, Y.-S. Kim, J.-G. In, D.-C. Yang, J.-S. Yi, and Y.-E. Choi Enhanced Triterpene and Phytosterol Biosynthesis in Panax ginseng Overexpressing Squalene Synthase Gene Plant Cell Physiol., August 15, 2004; 45(8): 976 - 984. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. W. Groenen, I. A. L. M. van Rooij, P. G. M. Peer, M. C. Ocke, G. A. Zielhuis, and R. P. M. Steegers-Theunissen Low Maternal Dietary Intakes of Iron, Magnesium, and Niacin Are Associated with Spina Bifida in the Offspring J. Nutr., June 1, 2004; 134(6): 1516 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tse, A. J. H. Smith, S. Hunt, I. Lavenir, A. Forster, A. J. Warren, G. Grutz, L. Foroni, M. B. L. Carlton, W. H. Colledge, et al. Null Mutation of the Lmo4 Gene or a Combined Null Mutation of the Lmo1/Lmo3 Genes Causes Perinatal Lethality, and Lmo4 Controls Neural Tube Development in Mice Mol. Cell. Biol., March 1, 2004; 24(5): 2063 - 2073. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Ohashi, J.-i. Osuga, R. Tozawa, T. Kitamine, H. Yagyu, M. Sekiya, S. Tomita, H. Okazaki, Y. Tamura, N. Yahagi, et al. Early Embryonic Lethality Caused by Targeted Disruption of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Gene J. Biol. Chem., October 31, 2003; 278(44): 42936 - 42941. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. E. Otto, C. J. Henderson, D. Carrie, M. Davey, T. E. Gundersen, R. Blomhoff, R. H. Adams, C. Tickle, and C. R. Wolf Identification of Novel Roles of the Cytochrome P450 System in Early Embryogenesis: Effects on Vasculogenesis and Retinoic Acid Homeostasis Mol. Cell. Biol., September 1, 2003; 23(17): 6103 - 6116. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Herman Disorders of cholesterol biosynthesis: prototypic metabolic malformation syndromes Hum. Mol. Genet., April 2, 2003; 12(90001): R75 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Devarenne, A. Ghosh, and J. Chappell Regulation of Squalene Synthase, a Key Enzyme of Sterol Biosynthesis, in Tobacco Plant Physiology, July 1, 2002; 129(3): 1095 - 1106. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Shen, K. A. O'Leary, and C. B. Kasper Association of Multiple Developmental Defects and Embryonic Lethality with Loss of Microsomal NADPH-Cytochrome P450 Oxidoreductase J. Biol. Chem., February 15, 2002; 277(8): 6536 - 6541. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Wassif, P. Zhu, L. Kratz, P. A. Krakowiak, K. P. Battaile, F. F. Weight, A. Grinberg, R. D. Steiner, N. A. Nwokoro, R. I. Kelley, et al. Biochemical, phenotypic and neurophysiological characterization of a genetic mouse model of RSH/Smith-Lemli-Opitz syndrome Hum. Mol. Genet., March 1, 2001; 10(6): 555 - 564. [Abstract] [Full Text] [PDF] |
||||